Subscribe
Pet Health & Wellness
6 min read

Ivan Zak | Co-Founder, Serenity Vet

After surviving burnout severe enough to nearly end his life, veterinarian Ivan Zak set out to fix the systems behind it. He bootstrapped SmartFlow and sold it to IDEXX, built the employee-owned group Galaxy Vets, and now co-leads Serenity Vet to tackle veterinary medicine's least-managed cost: labor. A candid conversation on burnout, ownership, private equity, and operational discipline.

Written by
Roy Ben-Tzvi
Published on
November 11, 2026
Ivan Zak, Co-Founder of Serenity Vet

Ivan Zak, DVM, MBA, Founder of Galaxy Vets, Co-Founder of Serenity Vet

When Ivan Zak hit rock bottom, he thought the problem was himself. Years spent working emergency shifts as a relief veterinarian had left him exhausted, burned out, and questioning whether he could continue. What he eventually discovered was that the crisis wasn’t personal, it was systemic. That realization would shape the next decade of his career.

Today, Zak is one of the most influential operators in veterinary medicine. He bootstrapped SmartFlow from a frustrating workflow problem inside emergency hospitals and eventually sold it to IDEXX. He launched Galaxy Vets to test whether employee ownership could create healthier workplaces. And now, through Serenity Vet, he’s tackling one of the profession’s most persistent challenges: labor efficiency. In this conversation, Zak reflects on burnout, entrepreneurship, private equity, employee ownership, and why operational excellence, not acquisitions, may ultimately determine the future of veterinary medicine.

Ivan Zak, veterinarian and founder, photographed for The Underbite

You survived burnout severe enough to attempt suicide, then turned it into a career mission. What made you run toward the problem instead of stepping back?

Finding a purpose and fully engaging in it.

Burnout can take away your joy. The things you used to love, even outside work, don’t feel fun anymore. For me, what helped was finding new happiness, a bigger goal that would excite me. That became looking for management solutions to burnout, and more specifically, solving inefficiencies in veterinary hospitals that were draining. I became curious about how to fix those systems, and that curiosity and sense of purpose gave me the energy to move forward.

More on Serenity Vet from The Underbite

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews